Zhejiang University

Shanghai Pharmaceuticals Holdings Co., Ltd.

Hangzhou Zede Pharma-tech Co. Ltd.

Yongping Yu

Wenteng Chen

Jing Jing Zhang

Jingkang Shen

Guangxin Xia

Yu Hao

Yu Zhang

Xin Yuan

Feng Han

Xuejun Liu

Chunchun Zhang

Bojun Li

Zudong Liu

Robert Charles Hider

Guolin Zhang

Zhi Li

Robert Hider

The present application provides the preparation and use of a 3,4-dihydroxyl-N-(1′-benzyl-2′-hydroxyethyl)-2-methyl pyridine chloride. According to the present application, a 3,4-dihydroxyl-N-(1′-benzyl-2′-hydroxyethyl)-2-methyl pyridine chloride is directly synthesized by a one-step reaction, and the compound includes a pharmaceutically acceptable salt thereof. 3,4-dihydroxyl-N-(1′-benzyl-2′-hydroxyethyl)-2-methyl pyridine chloride has been proved to have a good antiparkinsonian activity by animal tests, and it is a class of novel antiparkinsonian drug candidates. It can be used in the preparation of drugs for the treatment of a Parkinson's disease, and its structural formula (I) is as follows:

3,4-dihydroxy-n-(1'-benzyl-2′-hydroxyethyl)-2-methylpyridine chloride, and synthesis and use thereof

Disclosed are as represented by Formula (I) a quinazoline derivative and a pharmaceutical acceptable salt thereof, or, an enantiomer, a non-enantiomer, a tautomer, a racemate, a solvate, a metabolic precursor, or a prodrug of both. Also disclosed are a preparation method therefor, an intermediate, a pharmaceutical composition having the quinazoline derivative, and an application thereof. The quinazoline derivative of the present invention is provided with improved anti-tumor activity. 

Quinazoline derivative, preparation method therefor, intermediate, composition and application thereof

Growing community of inventors

Hangzhou, China

Yongping Yu